Skip to content

Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases

Mikkel Arendt, Raben Rosenberg, Leslie Foldager, Gurli Perto, Povl Munk‐Jørgensen

The British Journal of Psychiatry November 30, 2005 DOI: 10.1192/bjp.187.6.510 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Observational cohort Peer reviewed
Sample size 535
Population Patients treated for cannabis-induced psychotic symptoms in Denmark between 1994 and 1999, without prior psychotic symptoms
Duration At least 3 years of follow-up
Topics Cannabis
Citations 258
Key findings Schizophrenia-spectrum disorders were diagnosed in 44.5% of the sample, and new psychotic episodes of any type in 77.2%. Diagnosis was often delayed, with 47.1% receiving a schizophrenia-spectrum diagnosis more than a year after initial treatment. Patients developed schizophrenia at an earlier age than the comparison group (males, 24.6 vs. 30.7 years; females, 28.9 vs. 33.1 years).

Abstract

Background: Few studies have examined samples of people with cannabis-induced psychotic symptoms.

Aims: To establish whether cannabis-induced psychotic disorders are followed by development of persistent psychotic conditions, and the timing of their onset.

Method: Data on patients treated for cannabis-induced psychotic symptoms between 1994 and 1999 were extracted from the Danish Psychiatric Central Register. Those previously treated for any psychotic symptoms were excluded. The remaining 535 patients were followed for at least 3 years. In a separate analysis, the sample was compared with people referred for schizophrenia-spectrum disorders for the first time, but who had no history of cannabis-induced psychosis.

Results: Schizophrenia-spectrum disorders were diagnosed in 44.5% of the sample. New psychotic episodes of any type were diagnosed in 77.2%. Male gender and young age were associated with increased risk. Development of schizophrenia-spectrum disorders was often delayed, and 47.1% of patients received a diagnosis more than a year after seeking treatment for a cannabis-induced psychosis. The patients developed schizophrenia at an earlier age than people in the comparison group (males, 24.6 v. 30.7 years, females, 28.9 v. 33.1 years).

Conclusions: Cannabis-induced psychotic disorders are of great clinical and prognostic importance.

Comparable studies

Other observational and cohort studies on cannabis, most cited first.

Study Year Design Participants
High-potency cannabis and the risk of psychosis People with first episode of psychosis and healthy controls from the local population 2009 Case-control study n = 454
Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada Rural aboriginal population 2013 Observational study
Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) Otherwise healthy young people 2000 Observational
Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study Individuals from the general population in Germany aged 14-24 at baseline 2011 Observational cohort n = 1,923
Assessment of addiction severity among ritual users of ayahuasca Regular ayahuasca users (jungle-based and urban-based) and matched controls 2010 Observational cohort n = 127

Citations in the library

Explore topics